Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Biogen Inc has a consensus price target of $277.79 based on the ratings of 24 analysts. The high is $373 issued by Morgan Stanley on November 10, 2023. The low is $190 issued by Barclays on August 2, 2024. The 3 most-recent analyst ratings were released by Wedbush, RBC Capital, and Cantor Fitzgerald on September 23, 2024, September 19, 2024, and September 9, 2024, respectively. With an average price target of $263 between Wedbush, RBC Capital, and Cantor Fitzgerald, there's an implied 32.90% upside for Biogen Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Biogen (NASDAQ:BIIB) was reported by Wedbush on September 23, 2024. The analyst firm set a price target for $205.00 expecting BIIB to rise to within 12 months (a possible 3.59% upside). 68 analyst firms have reported ratings in the last year.
The latest analyst rating for Biogen (NASDAQ:BIIB) was provided by Wedbush, and Biogen maintained their neutral rating.
The last upgrade for Biogen Inc happened on December 7, 2023 when Raymond James raised their price target to $283. Raymond James previously had a market perform for Biogen Inc.
The last downgrade for Biogen Inc happened on February 14, 2024 when Wells Fargo changed their price target from $315 to $240 for Biogen Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biogen was filed on September 23, 2024 so you should expect the next rating to be made available sometime around September 23, 2025.
While ratings are subjective and will change, the latest Biogen (BIIB) rating was a maintained with a price target of $210.00 to $205.00. The current price Biogen (BIIB) is trading at is $197.89, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.